A carefully balanced range featuring beacon brands could be just the fix consumers are looking for.
Winter Medicines is an important category for retailers, worth more than £643m a year [Nielsen Scantrack, Total Coverage, 52 weeks to 08.08.26].
“Demand can surge during December, immediately after Christmas and into early January as people spend more time together and illnesses circulate [ibid],” says Robert Slater, Sales & Commercial Director, SHS Sales & Marketing. The firm represents Reckitt and Haleon and its portfolio features Lemsip, Strepsils, Beechams, Otrivine, Nurofen, Nuromol, Anadin and Panadol.
“Maintaining availability throughout this period is essential, because a missed sale caused by an empty shelf may also mean losing the shopper’s wider basket spend.”
Looking back at 2025, he observes that cold and flu season arrived early, peaking during October and November before falling back significantly after Christmas. However, sales remained resilient during the first half of 2026, with cold and flu remedies up 5%, decongestants up 4% and sore-throat treatments up 3% [Nielsen Winter Meds Category, Total Market Value Sales, 12 weeks to 16.05.26 versus the same period in 2025].
While retailers understandably focus on cough, cold and flu remedies, the season presents wider opportunities across OTC, believes SHS.
“Christmas is often a period of rich food, social occasions and greater indulgence, prompting shoppers to seek fast, trusted relief from indigestion and heartburn,” says Slater. “Stocking recognised products such as Gaviscon can therefore generate valuable incremental sales as customers look to ease the effects of festive excess.”
The self-care shift
The wider self-care trend is creating additional opportunities for retailers. According to the PAGB’s 2025 Self-Care Census, 84% of adults would choose self-care as their first healthcare option, while 91% have used an OTC medicine to treat a minor health condition in the past year. The study also found that three-quarters of GP appointments for self-treatable conditions resulted in advice to use OTC medicines.
“In the wake of Covid, consumers are increasingly willing to self-medicate rather than immediately visiting a doctor or pharmacy, with OTC medicines sales typically 30% ahead of where they were pre-Covid in the impulse channel [SHS Sales Out Account Data],” says Slater.
To maximise sales, SHS advises making medicines easy to find and shop.
“Although some retailers choose to keep OTC medicines behind the counter for safety reasons, trials have demonstrated that placing suitable products on the shop floor where shoppers can browse formats, compare trusted brands and select the most appropriate option can have a significant positive impact on sales.”
The PAGB’s 2025 Self-Care Census found that 61% of consumers say trust in a brand influences their OTC purchases, while 93% of branded OTC buyers use brand names to help them identify the right medicine.
SHS advises that the main fixture should be clearly organised by need, helping shoppers quickly navigate the different sub-categories across pain relief, cold and flu, sore throat, cough, decongestant and children’s remedies.
In addition, SHS data shows that winter medicines have delivered significant sales uplifts when sold from an FSDU, with some products achieving increases of more than 80% compared with being stocked behind the counter.
Format also matters. “Cold and flu remedy sales currently divide approximately into 50% tablets, 40% sachets and 10% liquids, so fixtures should broadly represent that balance,” says Slater.
Retailers who combine strong availability, recognised brands and effective merchandising can ensure winter medicines remain not only an essential shopper service but also a valuable source of incremental sales throughout the colder months.

